Background and Objective: Periodontitis is a highly prevalent chronic inflammatory disease that causes tooth loss, morbidity and confers an increased risk for systemic disease. Tissue destruction during periodontitis is due in large part to collagen-degrading matrix metalloproteinases (MMPs) released by resident cells of the periodontium in response to proinflammatory cytokines. Platelets are immune-competent blood cells with a newly recognized role in chronic inflammation; however, their role in the pathogenesis of periodontitis is undefined. Consequently, the objective of this study was to assess the effect of platelet factor 4 (PF4), a major platelet-derived cytokine, on MMP-1 (collagenase) expression in human gingival fibroblasts (HGFs).
Periodontitis is a chronic oral infection that affects approximately half of the adult US population (1) . The clinical course of the disease is characterized by degradation of the tooth-supporting connective tissues and alveolar bone, leading to eventual tooth loss. At the cellular level, the disease pathogenesis is governed by highly complex intra-and intercellular signaling pathways involving multiple cell types (2) . During periodontitis, connective tissue degradation is largely caused by the release of collagendegrading matrix metalloproteinases, such as MMP-1, from resident cells in the periodontium (3) . Notably, increased MMP-1 gene expression in gingival fibroblasts is partially attributed to signaling from monocytederived proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-a) (4, 5) . However, the precise molecular determinants of cytokine-driven MMP-1 upregulation in fibroblasts are not defined.
One biochemical mechanism responsible for MMP-1 expression in fibroblasts is the MAP kinase (MAPK) signaling pathway (6) (7) (8) . In this pathway, extracellular signaling molecules, including proinflammatory cytokines, trigger the sequential phosphorylation and activation of the proteins Ras, B-Raf, MEK1/2 and ERK1/2 (also known as p44/42) (9) . ERK then enters the fibroblast's nucleus where it activates the MMP-1 promoter, thus stimulating transcription of the MMP-1 gene. However, while monocyte-derived cytokines such as IL-1 and TNF-a have well established roles in MMP-1 induction, the contributions of other inflammatory cells and their cytokines to the transcriptional regulation of MMP-1 remain unidentified.
Platelets are small circulating blood cells that store and release an abundance of proinflammatory cytokines (10) . Multiple lines of evidence now indicate that platelets contribute to chronic inflammation. For example, arthritic disease is milder in thrombocytopenic mice compared to controls (11) . Similarly, asthmatic inflammation and bronchoconstriction are suppressed by platelet depletion (12) and platelet function is elevated in asthmatic humans (13) . In addition, platelets contribute to gut inflammation observed in ulcerative colitis and Crohn's disease (14) . Notably, recent evidence indicates that platelet counts and platelet activity are elevated in patients with periodontitis (15) (16) (17) .
The proinflammatory role of platelets is perhaps attributable to platelet factor 4 (PF4), a 7.8 kDa cytokine that accounts for the bulk of platelet alpha (a)-granule content (18) . PF4 has several proinflammatory functions, for example, by promoting neutrophil chemotaxis and activation (19, 20) , and by inducing cytokine production by monocytes (21) .
There is presently no knowledge on the specific role of PF4 in the context of periodontal disease pathogenesis. We hypothesized that PF4, as the major constituent of platelet a granules, could represent the missing link between activated platelets, the MAPK pathway and MMP-1 upregulation. To address this question at a fundamental level, we evaluated the role of PF4 in MMP-1 production by human gingival fibroblasts (HGFs). We found that HGFs cultured in the presence of PF4 showed a threefold increase in MMP-1 production and secretion relative to untreated controls. We also found that PF4 targets the p44/42 (ERK1/2) MAPK signaling pathway to promote MMP-1 transcription. Cells were maintained in a humidified incubator at 37°C with 5% CO 2 in alpha-MEM supplemented with 10% (v/v) fetal bovine serum and 5% (v/v) antibiotic solution and used for experiments between the fifth and eighth passages. Cells were seeded on to six-well tissue culture treated plates and allowed to reach 90-95% confluence. Cells were serum-starved for 24 h before stimulation with recombinant PF4.
Material and methods

Reagents
To study the effect of PF4 on the release of pro-MMP-1, serum-starved HGFs were treated with recombinant PF4 at various concentrations (ranging 10-200 ng/mL) and for various incubation times (ranging from 30 min to 6 h). The media was then harvested and centrifuged at 4°C. The concentration of pro-MMP-1 in the supernatants was determined by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). In some experiments, cells were pre-treated for 1 h with the cell-permeant inhibitor PD98059 (50 lM) to block the MAPK signaling pathway before the addition of PF4. Pro-MMP-1 release from HGFs was measured after 3 h of incubation with PF4.
After media collection, cells were immediately washed with ice-cold phosphate-buffered saline and solubilized in ice-cold lysis buffer. Cell lysates were clarified by centrifugation at 4°C. Protein samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred on to polyvinylidene fluoride membranes. Membranes were blocked and then probed overnight at 4°C with an antibody against phosphop44/42 MAPK (at a 1 : 2000 dilution in TBS-Tween). As a loading control, membranes were also probed with an antibody against GAPDH (1 : 1000 dilution in TBS-Tween).
Quantitative polymerase chain reaction
To evaluate the effect of PF4 on MMP-1 gene expression, serum-starved HGFs were cultured in the presence of PF4 (100 ng/mL) for 3 h; HGFs cultured with vehicle alone served as a negative control. Real-time polymerase chain reaction (PCR) was performed according to MIQE guidelines as described in detail previously (22) . Briefly, total RNA was isolated using a PureLink RNA mini kit in accordance with the manufacturer's protocol (Life Technologies). Next, total RNA (1 lg) was reverse transcribed using iScript Select cDNA Synthesis Kit (Bio-Rad, Mississauga, ON, Canada) and random oligodeoxynucleotide primers as per the manufacturer's instructions. Real-time PCR was performed using primers for MMP-1 (23) and using alpha-1,2-mannosyltranferase, GAPDH and beta-2-microglobulin as reference genes (24) . All PCR primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Real-time PCR amplification was performed using the CFX96 System (Bio-Rad) according to the following protocol: 1 cycle at 94°C for 3 min followed by 35 cycles at 94°C for 10 s, 60°C for 20 s and reaction completion with reading plate followed by melt curve analysis from 65°C to 95°C, 5 s each at 0.5°C. Non-transcribed RNA samples served as negative controls. Each PCR reaction was performed in triplicate. Following analysis, data was processed using the comparative C t method (CFX MANAGER Software Version 2.1; Bio-Rad).
Statistical analysis
The Student's t-test was used for comparisons involving only two groups. For the dose-response, time course and inhibition experiments, a one-way analysis of variance and Bonferroni post-hoc multiple comparison tests were used to evaluate the effects of PF4 treatment and/or MAPK inhibition on pro-MMP-1 release from HGFs. Values obtained from reverse transcription-quantitative PCR by the comparative C t method were log2 transformed for statistical testing. Statistical significance was set at p < 0.05. For statistical testing, each experiment was repeated a minimum of three times.
Results
Platelet factor 4 amplifies the release of matrix metalloproteinase-1 from gingival fibroblasts To improve our understanding of platelet-fibroblast interactions, HGFs were cultured in the presence or absence of recombinant PF4. The baseline concentration of pro-MMP-1 in the untreated HGF cultures was 0.90 AE 0.17 ng/mL (mean AE SD, n = 3). The effect of PF4 on pro-MMP-1 release by HGFs was quantified by enzyme-linked immunosorbent assay. We first evaluated the dose-response relationship between PF4 concentration and pro-MMP-1 secretion (Fig. 1) . Over the range of concentrations tested (10-200 ng/mL), PF4 induced a linear~0.5-3-fold increase in pro-MMP-1 release from HGFs, compared to untreated controls, although this was not statistically significant when the Bonferroni correction was applied to the analysis comparing all six test groups simultaneously (Fig. 1) . Similarly, our time course data show that PF4 (100 ng/ mL) triggers a significant (p < 0.05) and linear increase of pro-MMP-1 release over the 6 h test period (Fig. 2) .
PF4 increases MMP-1 gene transcription and protein expression
We then wished to determine whether the PF4 increases mRNA transcription of the MMP-1 gene or whether PF4 affects the exocytosis machinery of the fibroblast to enhance secretion. We used real-time PCR to quantify MMP-1 messenger RNA (mRNA) in HGFs cultured in the presence or absence of PF4. Cells treated with PF4 (100 ng/mL for 3 h) showed ã 3-fold increase (p < 0.001) in MMP-1 gene transcription relative to untreated controls (Fig. 3) .
PF4 augments p44/42 MAP kinase signaling in human gingival fibroblasts
Published data show that expression of the MMP-1 gene is controlled by the p44/42 MAPK (ERK) signaling pathway (6) . The activity of p44/42 MAPK is determined by its phosphorylation status (9) . To test the hypothesis that PF4 targets p44/42 to modulate MMP-1 expression, we used Western blotting to compare the levels of phosphorylated p44/42 (at threonine 202 and tyrosine 204) in HGFs cultured with and without PF4 for 6 h. Levels of phosphorylated p44/42 in the HGFs underwent a clear increase following PF4 treatment (Fig. 4A) . To test the significance of this finding with regards to pro-MMP-1 release, we employed the cellpermeant compound PD98059, which inhibits p44/42 MAPK (ERK1/2) by blocking the upstream MAPK kinase MEK1 (25) . In HGFs pre-treated with 50 lM of PD98059, PF4 did not induce a significantly (p > 0.05) greater release of pro-MMP-1 relative to untreated controls (Fig. 4B) . To confirm the role of MEK/ERK signaling in the transcriptional upregulation of MMP-1, we cultured HGFs pretreated for 1 h with PD184352 (Axon Medchem, Reston, VA, USA), another MEK1 inhibitor (26) . Inhibition of the MEK/ERK signaling module by PD184352 (2 lM) reduced MMP-1 gene expression relative to both control and PF4-treated cells (Fig. 4C) . These concordant results obtained with two different MEK1 inhibitors collectively indicate that PF4 targets the p44/42 signaling pathway to regulate MMP-1 expression.
Discussion
Platelets are emerging as key contributors to chronic inflammation (10, 27, 28) although their role in the pathogenesis of periodontitis is not well understood. In the present study, we observed that cultured HGFs treated with PF4 produced up to three times more MMP-1 relative to controls. It should be noted that we simultaneously tested six different concentrations of PF4 and applied the Bonferroni correction to compensate for multiple comparisons. Consequently, individual differences between groups did not reach statistical significance within our comprehensive analysis. This point notwithstanding, our central finding is validated by the consistency of the results we obtained from two independent and quantitative experimental approaches: enzymelinked immunosorbent assay analysis of secreted pro-MMP-1 and real-time PCR. Our PCR data suggest that PF4 targets the fibroblast's transcription machinery to enhance MMP-1 production rather than promote MMP-1 secretion through increased exocytosis. Other proinflammatory cytokines such as IL-1 and TNF-a are extensively documented in terms of their upregulation of MMP-1 expression in HGFs (4, 5) . However, the present study is the first to identify a function for PF4 in MMP-1 expression, thus introducing a previously unidentified role for platelet-derived cytokines in gene transcription. The PF4-induced MMP-1 expression is likely via a direct effect as it occurred within the first few hours after treatment. The physiologic concentration of PF4 in plasma is reported to be less than 10 ng/mL (29) . Our dose-response data show that pro-MMP-1 release was amplified by more than 50% at only slightly supra-physiologic Fig. 2 . Time-dependent effects of platelet factor 4 on pro-MMP-1 secretion from human gingival fibroblasts. Bar graph illustrates enzyme-linked immunosorbent assay analysis of the release of pro-MMP-1 from cultured human gingival fibroblasts treated with recombinant platelet factor 4 (100 ng/mL) for time periods ranging from 0 to 6 h. Data are expressed as mean AE SD with the untreated control (t = 0) cells set at 1, and are based on three independent experiments. *p < 0.05; ***p < 0.0001, based on Bonferroni multiple comparison tests. MMP, matrix metalloproteinase. Fig. 3 . PF4 upregulates matrix metalloproteinase-1 mRNA expression. Bar graph illustrates real-time PCR data of matrix metalloproteinase-1 transcription in human gingival fibroblasts cultured in the absence (control, white bar) or presence (PF4, black bar) of PF4 (100 ng/mL) for 3 h. Data are expressed as mean AE SD with the control group set at 1, and are based on three independent experiments. **p < 0.01 (Student's t-test). PF4, platelet factor 4.
concentrations of PF4 although this difference was not statistically significant in the context of our analysis. This finding nonetheless underscores PF4's potency as a proinflammatory mediator.
The importance of HGF-derived MMP-1 with respect to periodontal disease progression is well known (3), as is the role of MAPK signaling in the induction of MMP-1 gene expression (7, 8) . We found that p44/42 (ERK) phosphorylation was amplified by PF4 treatment, which is consistent with a recent report of increased ERK phosphorylation in PF4-treated lymphoblasts (30) . We confirmed the importance of p44/42 (ERK1/2) activation in pro-MMP-1 delivery as pro-MMP-1 secretion was attenuated by the MEK inhibitor PD98059. Similarly, blockade of MAPK signaling also abrogated PF4-driven increases in MMP-1 gene transcription. These data are consistent with published reports that p44/42 MAPK activation is responsible for MMP-1 expression (6). Taken together, our findings delineate a novel PF4-and ERK-driven pathway for MMP-1 expression in HGFs.
Our findings suggest that platelet activation promotes periodontal tissue degradation by stimulating MMP-1 production by gingival fibroblasts. These data could at least partially explain recent reports of elevated platelet counts (17, 31) and increased platelet activation (15, 16) in patients with chronic periodontitis. Conceivably, higher numbers of circulating and highly reactive platelets would release greater amounts of PF4 that would in turn potentiate MMP-1 production and release from gingival fibroblasts. In this context, increased PF4 secretion from platelets would be particularly plausible in patients with periodontitis given that platelets are directly activated by periodontal pathogens (32, 33) .
One limitation of the present study is that a receptor for the PF4 ligand is not identified. Potential candidate receptors could include receptor tyrosine kinases or G-protein coupled receptors, as these are known effectors of the MAPK pathway (34, 35) . Further research is required to elucidate definitively the mechanism(s) by which PF4 activates MAPK. In conclusion, the present study describes a PF4-mediated upregulation of MMP-1 in HGFs. From a broader perspective, this finding points to a previously unidentified role for platelets in the progression of periodontitis while yielding a novel insight into crosstalk between platelets and fibroblasts. , and HGFs pre-treated with the inhibitor PD184352 (2 lM) for 1 h before stimulation and incubation with PF4. Data are expressed as mean AE SD with the vehicle-treated control cells set at 1, and are based on three independent experiments. **p < 0.01; ***p < 0.001, based on Bonferroni multiple comparison tests. DMSO, dimethyl sulfoxide; HGFs, human gingival fibroblasts; MAPK, MAP kinase; MMP, matrix metalloproteinase; PF4, platelet factor 4.
